Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111725 | 0.74 | PGR (0.52) | PGRARNR3C1NR3C2 | |
| SCHEMBL5125520 | 0.72 | PGR (0.66) | PGRARNR3C1NR3C2 | |
| SCHEMBL5119188 | 0.71 | PGR (0.43) | PGRARNR3C1NR3C2 | |
| SCHEMBL10917362 | 0.71 | PGR (0.42) | PGRARNR3C1NR3C2 | |
| SCHEMBL3378589 | 0.70 | PGR (0.47) | PGRARNR3C1NR3C2 | |
| SCHEMBL10915272 | 0.69 | PGR (0.46) | PGRARNR3C1NR3C2 | |
| SCHEMBL10994244 | 0.69 | PGR (0.42) | PGRARNR3C1NR3C2 | |
| SCHEMBL5116200 | 0.69 | PGR (0.52) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL29710912 | 0.68 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL61925 | 0.68 | PGR (0.59) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2006010142-A2 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | NR3C2, MC2R, NR3C1 | PGR 194/4885AR 50/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.